Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study.
K S Dujardin, M Enriquez-Sarano, H V Schaff...
https://pubmed.ncbi.nlm.nih.gov/10199882/Actively Recruiting
Led by Na Homolce Hospital · Updated on 2026-02-17
217
Participants Needed
8
Research Sites
52 weeks
Total Duration
Researchers are evaluating the best timing for surgery in patients who have severe aortic regurgitation but do not yet show symptoms. This heart valve condition often affects younger men and can lead to serious heart changes if left untreated. The study compares early surgery guided by detailed heart imaging with the usual approach of monitoring patients and operating only when symptoms or advanced heart changes develop. The study involves two main groups one will receive early, state-of-the-art aortic valve surgery, including valve-sparing procedures or replacements, scheduled within three months after randomization. The other group will follow a watchful waiting strategy with regular check-ups and surgery only if clear indications arise during follow-up. All patients undergo advanced heart imaging, exercise tests, blood tests, and quality of life questionnaires at set intervals. Participants will have heart magnetic resonance imaging and echocardiography at the start and at 12 months, plus clinical exams and tests every six months. Researchers will monitor heart function, exercise capacity, blood markers, and quality of life. The main outcome is a composite safety and effectiveness measure 12 months after randomization. The study also tracks complications, hospitalizations, and survival over time, with careful follow-up planned through the study duration.
CONDITIONS
Early Aortic vaLve surgEry Versus wAtchful waitiNg Strategy in Severe Asymptomatic aOrtic reguRgitation
R
Radka Kočková, MD,PhD
J
Jan Vojáček, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Na Homolce Hospital
Lead Sponsor
University Hospital Hradec Kralove
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 day
Participants undergo baseline examinations including cardiac magnetic resonance imaging (CMR), echocardiography (ECHO), electrocardiography (ECG), blood tests, exercise stress test (CPET), and quality of life questionnaire.
1 visit (in-person)
Duration - Surgery within 3 months post-randomization
Participants randomized to early surgery undergo aortic valve surgery within 3 months after randomization with follow-up to assess recovery and outcomes.
1 surgical visit plus approximately 6 post-operative visits
Duration - Up to 12 months or until surgery is indicated
Participants randomized to watchful waiting are regularly monitored every 6 months with clinical examinations, echocardiography, and blood tests. Surgery is performed if guideline-based indications develop during follow-up.
Biannual visits every 6 months
Duration - 12 months post-enrollment
All participants undergo repeat CMR, exercise stress testing, and quality of life assessments 12 months after enrollment to evaluate heart function and treatment effects.
1 visit (in-person) plus regular follow-up visits every 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
K S Dujardin, M Enriquez-Sarano, H V Schaff...
https://pubmed.ncbi.nlm.nih.gov/10199882/Amgad Mentias, Ke Feng, Alaa Alashi...
https://pubmed.ncbi.nlm.nih.gov/27855803/William A Zoghbi, David Adams, Robert O Bonow...
https://pubmed.ncbi.nlm.nih.gov/28314623/Radka Kočková, Hana Línková, Zuzana Hlubocká...
https://pubmed.ncbi.nlm.nih.gov/31614523/Bernard Iung, Victoria Delgado, Raphael Rosenhek...
https://pubmed.ncbi.nlm.nih.gov/31510787/Milind Y Desai
https://pubmed.ncbi.nlm.nih.gov/31240183/Emmanuel Lansac, Laurent de Kerchove
https://pubmed.ncbi.nlm.nih.gov/29718164/Richard Paul Steeds, Saul G Myerson
https://pubmed.ncbi.nlm.nih.gov/32817242/Hector I Michelena, Siddharth K Prakash, Alessandro Della Corte...
https://pubmed.ncbi.nlm.nih.gov/24958752/Jan Vecera, Jozef Bartunek, Marc Vanderheyden...
https://pubmed.ncbi.nlm.nih.gov/25283687/Na Homolce Hospital
Lead Sponsor
University Hospital Hradec Kralove
Collaborating Sponsor